Burns, D. M., Rana, S., Martin, E., Nagra, S., Ward, J., Osman, H., . . . Chaganti, S. (2016). Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant.
シカゴスタイル引用形Burns, D M., et al. "Greatly Reduced Risk of EBV Reactivation in Rituximab-experienced Recipients of Alemtuzumab-conditioned Allogeneic HSCT." Bone Marrow Transplant 2016.
MLA引用形式Burns, D M., et al. "Greatly Reduced Risk of EBV Reactivation in Rituximab-experienced Recipients of Alemtuzumab-conditioned Allogeneic HSCT." Bone Marrow Transplant 2016.
警告: この引用は必ずしも正確ではありません.